NCT05572801 NOAC9 - Circulating Tumor DNA Guided Follow-Up in Anal Cancer
| NCT ID | NCT05572801 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Aarhus University Hospital |
| Condition | Anal Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2023-08-02 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2023-08-02 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study investigates if circulating tumor DNA can improve the detection of early treatment failure or recurrence in localized squamous cell carcinoma of the anus (SCCA) after curative chemoradiotherapy thereby increasing the potential for cure. This will be done by comparing the standard follow-up program with ctDNA guided imaging follow-up. Secondly, the aim is to establish early interventions against late morbidities.
Eligibility Criteria
Inclusion Criteria: * Patients with SCCA eligible for definitive (chemo)radiotherapy * ≥ 18 of years * Written and oral consent Exclusion Criteria: * Conditions that will contraindicate blood samples * Conditions that will contraindicate a PET-CT scan. * Potential lack of compliance to standard FU program and study participation.
Contact & Investigator
Karen-Lise G Spindler, Professor
PRINCIPAL INVESTIGATOR
Department of Experimental Clinical Oncology Aarhus Univeristy Hospital
Frequently Asked Questions
Who can join the NCT05572801 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Anal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05572801 currently recruiting?
Yes, NCT05572801 is actively recruiting participants. Contact the research team at k.g.spindler@rm.dk for enrollment information.
Where is the NCT05572801 trial being conducted?
This trial is being conducted at Herlev, Denmark, Vejle, Denmark, Aarhus, Denmark, Tampere, Finland and 9 additional locations.
Who is sponsoring the NCT05572801 clinical trial?
NCT05572801 is sponsored by Aarhus University Hospital. The principal investigator is Karen-Lise G Spindler, Professor at Department of Experimental Clinical Oncology Aarhus Univeristy Hospital. The trial plans to enroll 400 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.